These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17118998)

  • 1. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.
    Redman LM; de Jonge L; Fang X; Gamlin B; Recker D; Greenway FL; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2007 Feb; 92(2):527-31. PubMed ID: 17118998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men.
    Larsen TM; Toubro S; van Baak MA; Gottesdiener KM; Larson P; Saris WH; Astrup A
    Am J Clin Nutr; 2002 Oct; 76(4):780-8. PubMed ID: 12324291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
    Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity.
    Bhasin S; Parker RA; Sattler F; Haubrich R; Alston B; Umbleja T; Shikuma CM;
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1049-57. PubMed ID: 17164307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
    Weyer C; Tataranni PA; Snitker S; Danforth E; Ravussin E
    Diabetes; 1998 Oct; 47(10):1555-61. PubMed ID: 9753292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (-)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state.
    Kriketos AD; Thompson HR; Greene H; Hill JO
    Int J Obes Relat Metab Disord; 1999 Aug; 23(8):867-73. PubMed ID: 10490789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects.
    Buemann B; Toubro S; Astrup A
    Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1553-60. PubMed ID: 11126205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men.
    van der Beek CM; Canfora EE; Lenaerts K; Troost FJ; Damink SWMO; Holst JJ; Masclee AAM; Dejong CHC; Blaak EE
    Clin Sci (Lond); 2016 Nov; 130(22):2073-2082. PubMed ID: 27439969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a novel beta-adrenoceptor agonist (Ro 40-2148) on resting energy expenditure in obese women.
    Haesler E; Golay A; Güzelhan C; Schutz Y; Hartmann D; Jéquier E; Felber JP
    Int J Obes Relat Metab Disord; 1994 May; 18(5):313-22. PubMed ID: 7914795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.
    Chen KY; Muniyappa R; Abel BS; Mullins KP; Staker P; Brychta RJ; Zhao X; Ring M; Psota TL; Cone RD; Panaro BL; Gottesdiener KM; Van der Ploeg LH; Reitman ML; Skarulis MC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1639-45. PubMed ID: 25675384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial.
    Hoyos CM; Yee BJ; Phillips CL; Machan EA; Grunstein RR; Liu PY
    Eur J Endocrinol; 2012 Oct; 167(4):531-41. PubMed ID: 22848006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women.
    Alger S; Larson K; Boyce VL; Seagle H; Fontvieille AM; Ferraro RT; Rising R; Ravussin E
    Am J Clin Nutr; 1993 Feb; 57(2):120-6. PubMed ID: 8424378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
    Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of sibutramine on energy expenditure and body composition in obese adolescents.
    Van Mil EG; Westerterp KR; Kester AD; Delemarre-van de Waal HA; Gerver WJ; Saris WH
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1409-14. PubMed ID: 17264187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of multivitamin and mineral supplementation on adiposity, energy expenditure and lipid profiles in obese Chinese women.
    Li Y; Wang C; Zhu K; Feng RN; Sun CH
    Int J Obes (Lond); 2010 Jun; 34(6):1070-7. PubMed ID: 20142823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications.
    Snitker S; Fujishima Y; Shen H; Ott S; Pi-Sunyer X; Furuhata Y; Sato H; Takahashi M
    Am J Clin Nutr; 2009 Jan; 89(1):45-50. PubMed ID: 19056576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study.
    Scalfi L; D'Arrigo E; Carandente V; Coltorti A; Contaldo F
    Int J Obes Relat Metab Disord; 1993 Feb; 17(2):91-6. PubMed ID: 8384170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.